ArticleBMC microbiology2025
Performance evaluation of the Biosynex AMPLIQUICK Fecal Bacteriology PCR kit.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contributions of whole-genome sequencing to the epidemiological monitoring ofAntimicrobial agents and chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study assessed the clinical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit for detecting enteropathogenic bacteria in cases of acute community-acquired diarrhea. In total, 194 retrospectively collected and 207 prospectively collected stool samples were analyzed. In cases of discordant results between the AMPLIQUICK Fecal Bacteriology kit and initial status of the 401 stools, samples were reanalyzed using the Seegene Gastrointestinal Panel 1 and 2 kits or targeted PCR assays. Among the 401 samples, 190 were expected to be positive for Campylobacter spp. (C. jejuni or C. coli), 48 for Salmonella spp., 39 for Shigella spp./enteroinvasive Escherichia coli (EIEC), 21 for Yersinia enterocolitica, and 30 for enterohemorrhagic E. coli (EHEC). Additionally, 64 samples were expected to be negative. Nine other samples tested positive for either other enteropathogens (Aeromonas spp., Plesiomonas shigelloides, Vibrio spp., or Clostridioides difficile) or co-infections with two pathogens. Only three samples (four discrepancies) yielded discordant results with the AMPLIQUICK Fecal Bacteriology kit: one false positive for enterotoxigenic E. coli (ETEC), one false negative for EHEC, and one sample that was both falsely positive for Salmonella spp. and falsely negative for EHEC. The analytical performance was calculated using a composite reference standard (CRS) in the absence of a perfect gold standard. Due to the low number or absence of positive cases, the performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit could not be determined for Vibrio spp., Yersinia pseudotuberculosis, hypervirulent C. difficile strains, Cholera toxin, ETEC, 0157 EHEC and P. shigelloides. Using this CRS, positive, negative and overall agreement rates ranged from 98.24 to 100% for all the other pathogens. In conclusion, the Biosynex AMPLIQUICK Fecal Bacteriology kit enables comprehensive screening for key bacterial pathogens associated with gastrointestinal infections in a single PCR assay. With excellent clinical performance, it represents a reliable tool for the rapid and accurate diagnosis of bacterial gastroenteritis in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.